Document:

EX-10.7

 Exhibit 10.7 

 
 

 
 January 11, 2010 
 Mr. Scott Minick 
 69 Wellington Avenue 

San Anselmo, CA 94960 
  

	Re:	Employment Offer Letter 

 Dear Scott:

 I am pleased to provide you with the terms and conditions of your anticipated employment by BIND Biosciences, Inc. (the
“Company” or “BIND”). The following sets forth the terms and conditions of our offer of employment to you. 

1. Position. 

(a) You will be the President and Chief Executive Officer (“CEO”) of the Company, reporting to the Company’s board
of directors (“Board”). You will be expected to devote your full business time and your reasonable professional efforts to the performance of your duties and responsibilities for the Company and to abide by all Company policies and
procedures, as in effect from time to time. You will be expected to perform the duties of your position and such other duties as reasonably may be assigned to you from time to time by the Board. The Board will review your performance on an annual
basis. 
 (b) You will serve as a director on the Board for so long as you serve as the CEO or until your earlier death,
resignation or removal. In accordance with the Second Amended and Restated Voting Agreement dated as of July 22, 2009, among the Company and certain of its stockholders, as the same may be amended from time to time, you will occupy the position
designated for the CEO. Subject to the second sentence of Section 1(a) and to prior approval of the Board (which approval shall not be unreasonably withheld), you may serve as a director of up to two companies other than BIND as well as a role
as an affiliate of ARCH Venture Partners. The Board acknowledges and approves your current board seats at Sorbent Therapeutics and Chiasma and that you will serve as the point of contact for ARCH Venture Partners to the Company under this
Section 1b. 
 2. Starting Date/Nature of Relationship. If you accept this offer, your employment with the Company will begin
on January 11, 2010 (the “Start Date”). No provision of this letter shall be construed to create a promise of employment for any specific period of time. Your employment with the Company is at-will employment, which may be
terminated by you or the Company at any time for any reason. 

 January 11, 2010 
  Page
 2
 of 7 
  

 3. Compensation and Benefits. 

(a) The Company will pay you a base salary at the rate of $395,000 per year, payable in accordance with the regular payroll practices of
the Company, less any legally required deductions for federal and state taxes and the like, or other deductions which you authorize. 
 (b) In addition to your annual base salary, the Company will allow you non-exclusive use of company leased accommodations close to the Company offices for 1 year. The Company will also reimburse your
actual relocation expenses, not to exceed a total sum of $75,000, if in the first year or $50,000 if in the second year if in the second or later years, subject to your production of receipts for those expenses. In the event that you terminate your
employment for any reason other than Good Reason (as defined in Section 3e) within six months after the Start Date, then you shall promptly refund to the Company 50% of all amounts paid to you pursuant to this Section 3(b). The Company
will reimburse you for any income taxes incurred as a result of these relocation payments. The Company, through the Board’s Compensation Committee, agrees to consider changes to this relocation package at your request in light of future facts
and circumstances. 
 (c) Promptly after the Start Date, the Company shall sell you [1,158,069] shares (the
“Shares”) of the Company’s common stock, $0.0001 par value per Share (“Common Stock”), at a price of $0.46 per Share. The purchase and sale of Shares shall be made pursuant to the Company’s 2006 Stock
Incentive Plan and shall be governed by a Restricted Stock Purchase Agreement, substantially in the form of Exhibit 3(c) (the “Restricted Stock Purchase Agreement”), which shall contain, among other things, a right of the
Company to repurchase unvested Shares under certain circumstances. The Shares will be subject to vesting requirements such that: 8.33% of the Shares shall be vested on the Start Date; 22.91% of the Shares shall vest on January 11, 2011; and
1.91% of the Shares shall vest on the 11th day of each
month thereafter; for a total four-year vesting period, with accelerated vesting under certain circumstances, all as set forth in greater detail in the Restricted Stock Purchase Agreement. You may be eligible to receive additional stock options as
determined by the Compensations Committee and Board to ensure that your equity ownership in the Company remains competitive with CEO’s of comparable biotechnology companies. 

(d) To facilitate your purchase of the Shares, the Company shall make a full-recourse loan to you in the principal amount of $532,712.
The loan shall be evidenced by a promissory note from you to the Company in the form of Exhibit 3(d). The loan shall bear interest at the rate of 2.45% per annum and shall mature and be repaid to the Company on the earliest to occur of:
(i) an initial public offering of the Company; (ii) within 30 days after the voluntary termination of your employment with the Company without Good Reason, or involuntary termination with Cause; (iii) six months after other
termination of employment or (iv) January 11, 2018. 
 (e) In the event that your employment were to be terminated by
the Company without “Cause” or you resign your employment for “Good Reason” (as both terms are defined below), you will receive a severance benefit of up to twelve months of base salary continuation and up to twelve months of
reimbursement of COBRA premiums for medical insurance coverage, so long as you are eligible to elect COBRA benefits. In addition, you will receive vesting acceleration of twelve months from the date of termination. The Company’s severance
obligations may be conditioned upon your execution and delivery to the Company of a reasonable release of claims. 

 January 11, 2010 
  Page
 3
 of 7 
  

 “Cause” for termination shall mean: (i) commission of, or indictment or conviction
for, any felony or any crime involving moral turpitude; (ii) participation in any fraud against the Company; (iii) your substantial failure to perform (other than by reason of disability), or gross negligence in the performance of, your
duties and responsibilities to the Company or any of its affiliates; (iv) other conduct by you that is or could reasonably anticipated to be harmful to the business, interests or reputation of the Company or any of its affiliates; or
(v) your breach of any material provision of any agreement between you and the Company including this agreement and the Nondisclosure Agreement (as defined in Section 5). 
 “Good Reason” shall mean any termination of your employment by you immediately following any of the following: (i) a change in your principal work location despite your stated
disagreement with such a change, to a location more than 60 miles from the Company’s current location in Cambridge, Massachusetts (travel for Company business shall not be deemed a change in principal work location); (ii) a reduction by
the Company in your salary or benefits (provided, that if the Board has determined that it is in the best interests of the Company to reduce compensation and benefits generally, such reduction shall not qualify as a termination for Good Reason if
(a) the reduction of the salary and benefits is proportionate to the reduction imposed on other executives of the Company of similar seniority and (b) the reduction does not reduce the salary and benefits by more than 20% below the level
then in effect); or (iii) a reduction by the Company in your duties, position, title, or responsibilities (unless such reduction occurs after a Change of Control, as defined below, in which case a mere change in title or reporting
responsibilities shall not constitute Good Reason). 
 “Change of Control” means the closing of (i) a sale of all or
substantially all of the assets of the Company, or (ii) a stock tender or a merger, consolidation or similar event pursuant to a transaction or series of related transactions in which a third party acquires more than fifty percent (50%) of
the equity voting securities of the Company outstanding immediately prior to the consummation of such transaction or series of transactions, and the shareholders of the Company do not retain a majority of the equity voting securities of the
surviving entity, other than (x) a merger, conversion or other transaction the principal goal of which is to change the jurisdiction of incorporation of the Company, or (y) an equity security financing for the account of the Company in
which capital stock of the Company is sold to one or more institutional investors. 
 (f) You will be eligible to participate in
all employee benefit plans made generally available by the Company from time to time to its employees, subject to plan terms and generally applicable Company policies. These benefits, of course, may be modified or changed from time to time at the
sole discretion of the Board, and the provision of such benefits to you in no way changes or impacts your status as an at-will employee. 
 (g) You will be entitled to earn vacation in accordance with the Company’s policies from time to time in effect, in addition to holidays observed by the Company, subject to a minimum entitlement of
four weeks vacation. Vacation may be taken subject to the business needs of the Company, and otherwise shall be subject to the policies of the Company, as in effect from time to time. 

(h) The Company will pay or reimburse you for all reasonable business expenses incurred or paid by you in the performance of your duties
and responsibilities for the Company, subject to any maximum annual limit and other restrictions on such expenses set by the Company and to such reasonable substantiation and documentation as it may specify from time to time. 

 January 11, 2010 
  Page
 4
 of 7 
  

 4. Before You Start. Your employment with the Company is conditioned on your eligibility
to work in the United States. On or before the Start Date, you must complete an I-9 Form and provide the Company with any of the accepted forms of identification specified on the I-9 Form. A copy of an I-9 Form is enclosed for your information.
Please bring the appropriate documents listed on that form with you when you report to work. 
 5. Confidentiality and Other
Obligations. The Company considers the protection of its confidential information, proprietary materials and goodwill to be extremely important. Given the confidential nature of various aspects of our business, you may not discuss the fact
or terms of this offer or any employment discussions with anyone other than a member of the Board and members of your immediate family (and, if relevant, your financial advisor or lawyer). In addition, as a condition of this offer of employment, you
are required to carefully review and then sign the Employee Nondisclosure, Noncompetition and Assignment of Intellectual Property Agreement (the “Non-Disclosure Agreement”) enclosed with this letter. 

6. Legal Expenses. The Company shall reimburse you the reasonable fees and expenses of your legal counsel incurred in connection with this
offer of employment and all related documents and transactions contemplated thereby, up to a maximum payment for such fees and expenses of $7,500. 
 7. Conflicting Agreements. You hereby represent and warrant to the Company that your signing of this agreement and the performance of your obligations under it will not breach or be in
conflict with any other agreement to which you are a party or are bound, and that you are not now subject to any covenants against competition or similar covenants or any court orders that could affect the performance of your obligations under this
Agreement. You agree that you will not disclose to or use on behalf of the Company any proprietary information of a third party without that party’s consent. 
 8. Miscellaneous. This letter and the Non-Disclosure Agreement constitute our entire offer regarding the terms and conditions of your prospective employment with the Company. It supersedes
any prior proposals, agreements, or other promises or statements (whether oral or written) regarding the offered terms of employment. The terms of your employment shall be governed by the laws of The Commonwealth of Massachusetts, without regard to
its principles of conflicts of laws. 
 [Signature page follows] 

 January 11, 2010 
  Page
 5
 of 7 
  

 If the terms of this offer are acceptable to you, please sign this letter in the place provided and
return it to me no later than January 8, 2010. Your signature on the copy of this letter and your delivery of the signed copy to the Company will evidence your agreement with the terms and conditions set forth herein. 

We are excited to offer you the opportunity to lead the BIND team as its CEO, and we look forward to working with you in this new capacity. We are
confident that you will make a major contribution to our unique and exciting enterprise. 
  

	
	Sincerely,
	
	 /s/ Andrea Franz

	Andrea Franz
	Chief Financial Officer

 Accepted and Agreed as of January 11, 2010 

 

	
	 /s/ Scott Minick

	Scott Minick

 January 11, 2010 
  Page
 6
 of 7 
  

 Exhibit 3(c) 
 Restricted Stock Purchase Agreement 

 RESTRICTED STOCK PURCHASE AGREEMENT 

(Scott Minick) 

This Restricted Stock Purchase Agreement (this “Agreement”) dated as of January 11, 2010 (the “Effective
Date”), is made by and between BIND Biosciences, Inc., a Delaware corporation (the “Company”), and Scott Minick (“Purchaser”). 
 WHEREAS, the Company and Purchaser have entered into that certain employment offer letter agreement of even date herewith (the “Employment Agreement”), pursuant to which Purchaser shall
serve as an employee and officer of the Company; and 
 WHEREAS, the Company desires to sell to Purchaser, and Purchaser desires
to purchase from the Company, 1,158,706 shares of the Company’s Common Stock, $0.0001 par value per share (“Common Stock”). 
 NOW, THEREFORE, in consideration of the premises and the promises set forth herein, and for other good and valuable consideration, the parties agree as follows: 

1. Definitions. As used in this Agreement, the following terms shall have the following meanings: 

Act: The Securities Act of 1933, as amended. 
 Change of Control: The closing of (i) a sale of all or substantially all of the assets of the Company, or (ii) a stock tender or a merger, consolidation or similar event pursuant to a
transaction or series of related transactions in which a third party acquires more than fifty percent (50%) of the equity voting securities of the Company outstanding immediately prior to the consummation of such transaction or series of
transactions, and the shareholders of the Company do not retain a majority of the equity voting securities of the surviving entity, other than (x) a merger, conversion or other transaction the principal goal of which is to change the
jurisdiction of incorporation of the Company, or (y) an equity security financing for the account of the Company in which capital stock of the Company is sold to one or more institutional investors. 

Good Reason: shall mean any termination of Purchaser’s employment by Purchaser immediately following any of the following:
(i) a change in Purchaser’s principal work location despite Purchaser’s stated disagreement with such a change, to a location more than 60 miles from the Company’s current location in Cambridge, Massachusetts (travel for Company
business shall not be deemed a change in principal work location); (ii) a reduction by the Company in Purchaser’s salary or benefits (provided, that if the Board has determined that it is in the best interests of the Company to reduce
compensation and benefits generally, such reduction shall not qualify as a termination for Good Reason if (a) the reduction of the salary and benefits is proportionate to the reduction imposed on other executives of the Company of similar
seniority and (b) the reduction does not reduce the salary and benefits by more than 20% below the level then in effect); or (iii) a reduction by the Company in Purchaser’s duties, position, title, or responsibilities (unless such
reduction occurs after a Change of Control in which case a mere change in title or reporting responsibilities shall not constitute Good Reason). 

 Service: Service to the Company in the role of a director, officer, employee or
consultant of the Company. 
 Shares: The shares of Common Stock issued to Purchaser hereunder and any other securities
of the Company which may be issued in exchange for or in respect of such shares of Common Stock, whether by way of stock split, stock dividend, combination of shares, reclassification, recapitalization, reorganization or any other means. 

Unvested Shares: Any Shares that are not Vested Shares. 
 Vested: Released from the Company’s Repurchase Option (as defined in Section 5(a)). 
 Vested Shares: Any Shares that have Vested in accordance with Section 5(b). 
 2. Purchase and Sale of Shares. Pursuant to the terms and conditions set forth in this Agreement, the Company hereby sells to Purchaser, and Purchaser hereby purchases from the Company, 1,158,706
shares of the Company’s Common Stock for a purchase price per share of $0.46, and an aggregate purchase price of $533,005. The Company acknowledges receipt from Purchaser of a full-recourse promissory note in the principal amount of $533,005,
as full consideration for such purchase price. Purchaser and the Company hereby agree that the fair market value of the Shares on the date hereof is $0.46 per share. 
 3. Representations of Purchaser. Purchaser understands that the Shares are not registered under the Act, and represents to the Company, and agrees that the Company is entitled to rely on such
representations, as follows: 
 (a) Purchaser understands that the Shares have not been registered under the Act, or registered
or qualified under the securities or “Blue Sky” laws of any jurisdiction, and are being sold pursuant to exemptions contained in the Act and exemptions contained in other applicable securities or “Blue Sky” laws. Purchaser
understands further that the Company’s reliance on these exemptions is based in part on the representations made by Purchaser in this Agreement. In this connection, Purchaser represents and warrants that the offer and sale of the Shares were
made solely in Massachusetts. 
 (b) Purchaser understands the term “accredited investor” as used in Regulation D
promulgated under the Act and represents and warrants to the Company that he is an “accredited investor” for purposes of acquiring the Shares. The nature and amount of Purchaser’s investment in the Shares is consistent with
Purchaser’s investment objectives, abilities and resources. Purchaser understands that the Shares are an illiquid investment, which will not become freely transferable by reason of any “change of circumstances” whatever. Purchaser has
adequate means of providing for Purchaser’s current needs and possible contingencies and has no need for liquidity in Purchaser’s investment. 
 (c) Purchaser is acquiring the Shares for Purchaser’s own account for investment, and not for, with a view to, or in connection with the resale or distribution thereof. Purchaser has no present
intention to sell, hypothecate, distribute or otherwise transfer the Shares or any portion thereof or any interest therein. 

  
 2 

 (d) Purchaser understands that the Shares will constitute “restricted securities”
within the meaning of Rule 144 promulgated under the Act and that, as such, the Shares must be held indefinitely unless they are subsequently registered under the Act or unless an exemption from the registration requirements thereof is available.
Purchaser has been advised that Rule 144, which permits the resale, subject to various terms and conditions, of small amounts of such “restricted securities” after they have been held for one year, does not now apply to the Company,
because the Company is not now required to file, and does not file, current reports under the Securities Exchange Act of 1934, and because information concerning the Company substantially equivalent to that which would be available if the Company
were required to file such reports is not now publicly available. The Company may become a reporting entity at some future date, but no assurance can be given that it will do so. 

(e) In connection with Purchaser’s acquisition of the Shares, Purchaser accepts the condition that the Company may maintain
“stop transfer” orders with respect to the Shares and that each certificate or other document evidencing the Shares will bear conspicuous legends in substantially the form set forth in Section 7 of this Agreement. 

(f) Purchaser has consulted Purchaser’s attorney or accountant with respect to Purchaser’s purchase of the Shares. Purchaser
has fully investigated the Company and its business and financial condition and has knowledge of the Company’s current activities. Purchaser acknowledges that the Company has granted Purchaser and Purchaser’s attorney or accountant access
to all information about the Company which they have requested and has offered each of them access to all further information which they deemed relevant to an investment decision with respect to the Shares. Purchaser and Purchaser’s attorney or
accountant have had the opportunity to ask questions of, and receive answers from, representatives of the Company concerning such information and the Company’s financial condition and prospects. 

4. Restrictions on Transfer. The following restrictions on transfer of the Shares shall apply: 

(a) Securities Laws. Except for purchases of Unvested Shares by the Company as contemplated by Section 5, no Shares, nor any
interest therein, may be sold, assigned, pledged or otherwise transferred at any time or under any circumstances unless (i) the Shares proposed to be transferred have been registered under the Act and qualified under applicable state securities
laws, or (ii) the Company has received, or agreed to waive, an opinion of counsel acceptable to the Company to the effect that such transfer may be effected without registration under the Act or qualification under the securities laws of
relevant states and the proposed transferee has made such representations and agreements as the Company shall require to assure compliance with the Act and such laws. 
 (b) Termination of Repurchase Option. Except for purchases of Unvested Shares by the Company as contemplated by Section 5, no Shares, nor any interest therein, may be sold, assigned, pledged
or otherwise transferred until the Repurchase Option shall have terminated with respect to such Shares. 

  
 3 

 (c) Right of First Refusal and Co-Sale. As a condition precedent to the
Company’s issuance and sale of the Shares, Purchaser shall enter into that certain Second Amended and Restated Right of First Refusal and Co-Sale Agreement dated as of July 22, 2009, among the Company and certain of its stockholders (as
the same may be amended from time to time, the “ROFR and Co-Sale Agreement”) and assume the duties of, and be bound by the restrictions applicable to, a Restricted Stockholder. 

(d) Voting Agreement. As a condition precedent to the Company’s issuance and sale of the Shares, Purchaser shall enter into
that certain Second Amended and Restated Voting Agreement dated as of July 22, 2009, among the Company and certain of its stockholders (as the same may be amended from time to time, the “Voting Agreement”) and assume the duties
of, and be bound by the restrictions applicable to, an Executive Officer. 
 (e) Permitted Transfers. Any portion or all
of the Vested Shares may, without compliance with the provisions of Section 4(b), be transferred by Purchaser to a member of his immediate family or to a family partnership or family trust, or on Purchaser’s death may be transferred to
Purchaser’s estate or to those entitled to a distribution of the Vested Shares under the laws of descent and distribution, provided that Shares that are so transferred shall remain subject to this Section 4 and as a condition to any
transfer Purchaser shall obtain a written agreement from the transferee by which the transferee agrees to be bound by this Section 4. 
 (f) Remedies. No sale, assignment, pledge or other transfer of Shares shall be effective or given effect on the books of the Company unless all of the applicable provisions of this Section 4
have been duly complied with. If any transfer of Shares is made or attempted in violation of such restrictions, or if Shares are not offered to the Company as required hereby, the Company shall have the right to purchase such Shares from the
purported owner thereof or his transferee at any time before or after the transfer, as herein provided. In addition to any other legal or equitable remedies which it may have, the Company may enforce its rights by actions for specific performance
(to the extent permitted by law) and may refuse to recognize any transferee as one of its stockholders for any purpose, including, without limitation, for purposes of dividend and voting rights, until all applicable provisions hereof have been
complied with. 
 (g) Lock-Up. Purchaser agrees that for a period of up to 180 days from the effective date of any
registration of securities of the Company (upon request of the Company or the underwriters managing any underwritten offering of the Company’s securities), he will not sell, make any short sale or loan of, grant any option for the purchase of,
or otherwise dispose of any Shares held by him without the prior written consent of the Company or such underwriters, as the case may be. 
 5. Repurchase of Unvested Shares. 
 (a) Repurchase Option.

 (i) In the event of the termination of Purchaser’s Service by Purchaser or the Company for any reason, with or without
cause, the Company shall upon the date of such termination (the “Termination Date”) have an irrevocable, exclusive option (the “Repurchase Option”) for a period of 90 days from such date to repurchase all or any
portion of the Unvested 

  
 4 

 
Shares at the per share repurchase price of $0.46 per share, appropriately adjusted in the event of a stock dividend, stock split, recapitalization, combination of shares or similar event
occurring subsequent to the date of this Agreement. 
 (ii) Unless the Company notifies Purchaser within 90 days from the date
of termination of Purchaser’s Service that it does not intend to exercise its Repurchase Option with respect to some or all of the Unvested Shares, the Repurchase Option shall be deemed automatically exercised by the Company as of the 90th day
following such termination, provided, that the Company may notify Purchaser that it is exercising its Repurchase Option as of a date prior to such 90th day. Unless Purchaser is otherwise notified by the Company pursuant to the preceding
sentence that the Company does not intend to exercise its Repurchase Option as to some or all of the Unvested Shares to which it applies at the time of termination, execution of this Agreement by Purchaser constitutes written notice to Purchaser of
the Company’s intention to exercise its Repurchase Option with respect to all Unvested Shares to which such Repurchase Option applies. The Company, at its choice, may satisfy its payment obligation to Purchaser with respect to exercise of the
Repurchase Option by any of (1) delivering a check to Purchaser in the amount of the purchase price for the Unvested Shares being repurchased, (2) in the event Purchaser is indebted to the Company, canceling an amount of such indebtedness
equal to the purchase price for the Unvested Shares being repurchased and (3) by a combination of (1) and (2) so that the combined payment and cancellation of indebtedness equals such purchase price. The Company shall use good faith
efforts to satisfy its payment obligation to Purchaser within 15 days after Company’s notice of exercise of the Repurchase Option (or deemed exercise), and that if such payment is not effective within such 15 days from such date, the amount of
the Company’s unsatisfied payment obligation shall bear interest at a rate of nine percent (9%) per annum until the Company has satisfied its payment obligation under this Section 5(a)(ii). In the event of any deemed automatic
exercise of the Repurchase Option pursuant to this Section 5(a)(ii) at such time as Purchaser is indebted to the Company, the portion of such indebtedness equal to the purchase price of the Unvested Shares being repurchased shall be deemed
automatically canceled as of the date of Company’s notice of exercise of the Repurchase Option (or deemed exercise). As a result of any repurchase of Unvested Shares pursuant to this Section 5(a), the Company shall become the legal and
beneficial owner of the Unvested Shares being repurchased and shall have all rights and interest therein or related thereto, and the Company shall have the right to transfer to its own name the number of Unvested Shares being repurchased by the
Company, without further action by Purchaser. 
 (b) Vesting. 

(i) The Shares will become Vested as follows: 
 (1) 8.33% of the Shares shall vest on the Effective Date; 
 (2) An additional
22.91% of the Shares shall vest on January 11, 2011; and 

	

  
 5 

 (3) An additional 1.91% of the Shares shall vest on the 11th day of each month thereafter,
so that the Shares shall be fully Vested on the fourth anniversary of the Effective Date; 
 provided, however, that the
vesting of Shares on any such vesting date shall be conditioned upon Purchaser’s continuing Service to the Company from the date hereof through such vesting date. 
 (ii) Notwithstanding Section 5(b)(i), all Shares shall be deemed to have Vested after both of the following two conditions have been satisfied (A) a Change of Control, and (B) the
termination of Purchaser’s Service by the Company (or its successor, as the case may be) after such Change of Control or Resignation For Good Reason after such Change of Control. 

(iii) Notwithstanding Section 5(b)(i) and 5(b)(ii) an additional 22.92% of the Shares shall be deemed to have Vested if the
Purchaser is terminated without Cause or if Purchaser shall resign for Good Reason. If the aggregate of unvested Shares remaining is less than 22.92% of the Shares, then all Shares shall be deemed Vested if the Purchaser is terminated without Cause
or resigns for Good Reason. 
 6. Custody of Certificates. In order to facilitate the exercise of the Repurchase Option,
the Company or its counsel shall hold all certificates representing Unvested Shares, together with an adequate number of undated and otherwise blank stock powers executed by Purchaser. The Company shall have the right to cause transfers of Unvested
Shares to be effected pursuant to Section 4. After any Shares become Vested Shares, the Company shall, upon request of Purchaser, deliver to Purchaser a certificate or certificates representing such Vested Shares. After the Company sends
Purchaser a notice that it does not intend to exercise its Repurchase Option as to certain Unvested Shares, the Company shall, upon request of Purchaser, deliver to Purchaser a certificate or certificates representing such Unvested Shares.

 7. Legends. Each certificate representing Shares shall prominently bear legends in substantially the following forms:

 The securities represented by this certificate have been acquired for investment and have not been registered under the
Securities Act of 1933. Such securities may not be sold, transferred, pledged or hypothecated unless the registration provisions of said Act have been complied with or unless the Corporation has received an opinion of counsel reasonably satisfactory
to the Corporation that such registration is not required. 
 The securities represented by this certificate have been acquired
for investment and have not been registered or qualified under the securities or “Blue Sky” laws of any jurisdiction. Such securities may not be sold, transferred, pledged or hypothecated unless the registration, qualification and filing
requirements of all applicable jurisdictions have been satisfied or the Corporation has received an opinion of counsel reasonably satisfactory to the Corporation that the proposed transaction will be exempt from registration, qualification, and
filings in all such jurisdictions. 
 The Corporation is authorized to issue more than one class of stock. The powers,
designations, preferences and relative participating, optional or other special rights, and 

  
 6 

 
the qualifications, limitations or restrictions of such preferences and/or rights of each class of stock or series of any class are set forth in the Certificate of Incorporation of the
Corporation. The Corporation will furnish a copy of the Certificate of Incorporation of the Corporation to the holder hereof without charge upon written request. 
 The securities represented by this certificate are subject to restrictions on transfer and repurchase rights pursuant to the terms of a Restricted Stock Purchase Agreement, as amended from time to time,
between the owner of this certificate and the Corporation. The Corporation will furnish a copy of this agreement to the holder hereof without charge upon written request. 
 8. Miscellaneous. 
 (a) Entire Agreement. This Agreement constitutes
the entire agreement between the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written or oral, relating to such subject matter. 

(b) Amendments. Neither this Agreement nor any provision hereof may be changed or modified except by an agreement in writing
executed by Purchaser and on behalf of the Company. 
 (c) Binding Effect of the Agreement. This Agreement shall inure to
the benefit of, and be binding upon, the Company, Purchaser and their respective estates, heirs, executors, transferees, successors, assigns and legal representatives. 
 (d) Provisions Severable. In the event that any one or more of the provisions contained herein shall, for any reason, be held to be invalid, illegal, or unenforceable in any respect, such
invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement, and all other provisions shall remain in full force and effect. If any of the provisions of this Agreement is held to be excessively broad, it shall
be reformed and construed by limiting and reducing it so as to be enforceable to the maximum extent permitted by law. 
 (e)
Notices. All notices under this Agreement shall be effective (i) upon personal or facsimile delivery, (ii) two business days after deposit in the United States mail as registered or certified mail postage fully prepaid, or
(iii) one business day after pickup by any overnight commercial courier service, in each case sent or addressed to the Company at its principal office or to Purchaser at his record address as carried in the stock records of the Company, as the
case may be, or at such other address as either may from time to time designate in writing to the other. 
 (f)
Construction. A reference to a Section shall mean a Section of this Agreement unless otherwise expressly stated. The titles and headings herein are for reference purposes only and shall not in any manner limit the construction of this
Agreement which shall be considered as a whole. The words “include,” “includes” and “including” when used herein shall be deemed in each case to be followed by the words “without
limitation.” Whenever the context may require, any pronouns used herein shall include the corresponding masculine, feminine or neuter forms, and the singular form of names and pronouns shall include the plural and vice-versa. 

  
 7 

 (g) No Employment or Consulting Agreement. This Agreement shall not be construed as
an agreement by the Company to employ or engage Purchaser, nor is the Company obligated to employ or engage Purchaser by reason of this Agreement or the issuance of the Shares to Purchaser. 

(h) Section 83(b) Election. Purchaser will furnish to the Company a copy of any election made by Purchaser under
Section 83(b) of the Internal Revenue Code of 1986, as amended, with respect to his acquisition of the Shares. 
 (i)
Applicable Law. This Agreement shall be construed and enforced in accordance with the laws of The Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. Purchaser consents to jurisdiction and venue in any state
or federal court in The Commonwealth of Massachusetts for the purposes of any action relating to or arising out of this Agreement or any breach or alleged breach hereof, and to service of process in any such action by certified or registered mail,
return receipt requested. 
 (j) Disposition of Shares; Purchase by Nominee or Designee. Any Shares that the Company
elects to purchase hereunder may be disposed of by it in such manner as it deems appropriate with or without restrictions on the transfer thereof, and the Company may require their transfer to a nominee or designee as part of any purchase of Shares
from Purchaser. 
 (k) Withholding Taxes. Purchaser acknowledges and agrees that the Company has the right to deduct from
payments of any kind otherwise due to Purchaser any federal, state or local taxes of any kind required by law to be withheld with respect to the purchase of the Shares by Purchaser. 

[remainder of page intentionally left blank] 

  
 8 

 IN WITNESS WHEREOF, the parties hereto have executed this Restricted Stock Purchase
Agreement as of the date first above written. 
  

			
	BIND BIOSCIENCES, INC.
		
	By:	 	  

	Name:	 	Andrea Franz
	Title:	 	Chief Financial Officer
	
	PURCHASER:
	
	  

	Scott Minick

  
 9 

 STOCK POWER 
 (Scott Minick) 
 FOR VALUE RECEIVED, Scott Minick hereby sells, assigns and
transfers to BIND Biosciences, Inc., a Delaware corporation (the “Company” ), a total of                  shares of the Common Stock of the Company
standing in his name on the books of the Company represented by stock certificate number              to be delivered herewith, and does hereby irrevocably constitute and appoint Foley Hoag
LLP as attorney to transfer said shares on the books of the Company with full power of substitution in the premises. 
 Dated: 

 

	
	  

	Scott Minick

 In the Presence of: 
  

	
	  

	Name:

 January 11, 2010 
  Page
 17
 of 7 
  

 Exhibit 3(d) 
 Promissory Note 

 PROMISSORY NOTE 

 

			
	 $533,005
	 	January 11, 2010

 FOR VALUE RECEIVED, Scott Minick (“Minick”) hereby promises to pay to the order of BIND
Biosciences, Inc., a Delaware corporation (“BIND”), the aggregate principal amount of Five Hundred Thirty-Three Thousand Five Dollars ($533,005), together with simple interest on the unpaid principal balance at the rate of
2.45% per annum, on or before January 11, 2018, or as earlier provided in Sections 1 and 3 below, subject to the terms set forth in this promissory note (this “Note”). All terms used herein without definition herein shall
have the meanings ascribed to them in that certain Employment Offer Letter, dated as of January 11, 2010 (the “Offer Letter”), by and among BIND and Minick. 

1. Payment of principal and interest shall be made in lawful money of the United States of America, by check sent to BIND at its
principal offices, or at such other place as BIND shall have designated to Minick in writing. All payments shall be credited first to the accrued interest then due and the remainder to principal. Minick may prepay this Note at any time without
premium or penalty; provided, however, that all prepayments of principal shall be applied in the reverse order of maturity. 
 2. In the event this Note is not paid when due, Minick agrees to pay, in addition to the principal and interest, all costs of collection, including reasonable attorneys’ fees, and interest thereon at
the rate set forth above. 
 3. The entire principal balance of this Note and any unpaid accrued interest shall become
immediately due and payable without notice or demand: 
 (a) Upon the appointment of a receiver of any of Minick’s
property, the assignment or trust mortgage for the benefit of Minick’s creditors, the commencement of any kind of insolvency proceedings under any bankruptcy or other law relating to the relief of debtors, or the entry of an order for relief
with respect to Minick in any proceeding pursuant to the United States Bankruptcy Code, as amended; 
 (b) Upon such date that
Minick resigns or is involuntarily terminated as an employee, consultant or a director of BIND if such resignation is not for Good Reason or such termination is with Cause; 
 (c) Six months following such date that Minick resigns or is involuntarily terminated as an employee, consultant or a director of BIND if such resignation is for Good Reason or such termination is without
Cause; or 
 (d) Immediately prior to BIND’s filing of a registration statement with the Securities and Exchange Commission
pursuant to Section 12 of the Securities Exchange Act of 1934. 
 4. No course of dealing of BIND nor any failure or delay
by BIND to exercise any right, power or privilege under this Note shall operate as a waiver hereunder or thereunder and any single or partial exercise of any such right, power or privilege shall not preclude any later exercise thereof or any
exercise of any other right, power or privilege hereunder or thereunder. 

  

 
Minick and every maker, endorser and guarantor of this Note or the obligations represented hereby waives presentment, demand, notice, protest and all other demands and notices in connection with
the delivery, acceptance, performance, default or enforcement of this Note, assents to any extension or postponement of the time of payment or any other indulgence, to any substitution, exchange or release of collateral and to the addition or
release of any other party or person primarily or secondarily liable. No covenant, obligation or other provision of this Note may be waived, and no consent contemplated hereby may be given, other than in a writing signed by BIND. BIND shall have
full recourse against Minick, and shall not be required to proceed against any collateral securing this Note in the event of default. 
 5. The provisions of this Note shall be governed by, and construed and enforced in accordance with, the substantive laws of The Commonwealth of Massachusetts, without regard to its principles of conflicts
of laws. This Note may not be changed or terminated orally. 
 *    *    * 

IN WITNESS WHEREOF, the parties have executed this Promissory Note as an instrument under seal as of the date first above written.

  

			
	BIND BIOSCIENCES, INC.
		
	By:	 	  

	Name:	 	Andrea Franz
	Title:	 	Chief Financial Officer
	
	BORROWER:
	
	  

	Scott Minick
		
	Address:EX-10.8

 Exhibit 10.8 

 

			
	CONSULTANT:	  	  ̈      Greg Berk

	BIND CONTACT:	  	  ̈      Scott Minick

	EFFECTIVE DATE:	  	  ̈      May 15, 2012

  
  

CONSULTING AGREEMENT 

This Consulting Agreement (together with its attachments, this “Agreement”) made as of the date written above (the “Effective Date”)
is between BIND Biosciences, Inc., a Delaware corporation having an address at 325 Vassar St, Cambridge, MA 02139; (“BIND”) and the consultant named on the signature page (“Consultant”). BIND desires to have the benefit of
Consultant’s knowledge and experience, and Consultant desires to provide consulting services to BIND, all as provided in this Agreement. 
  

	1.	Definitions. The following terms have the meanings set forth below: 

 

	 	1.1	“Business Terms Exhibit” means the business terms and conditions set forth in the attached exhibit. 

 

	 	1.2	Confidential Information” means any non-public scientific, technical, trade or business information possessed or obtained by, developed for or given to BIND
which is treated by BIND as confidential or proprietary, whether or not labeled or identified as “Confidential”. Confidential Information will include, without limitation, information prepared in full or in part for BIND by Consultant,
Materials and Developments (defined below) and information about or belonging to BIND’s suppliers, licensors, licensees, partners, affiliates, customers, potential customers or others. 

 

	 	1.3	“Developments” means concepts, inventions, know-how, techniques, improvements, writings, data, computer software, Materials and rights (whether or not
patentable or subject to copyright or trade secret protection) that Consultant makes, conceives or reduces to practice, either alone or jointly with others, and that result from the performance of the Consulting Services (defined below), and/or
result from use Confidential Information of BIND. 

  

	 	1.4	“Materials” means all materials furnished by BIND, all materials developed by Consultant in connection with the Consulting Services, and any materials,
the cost of which are reimbursed to Consultant by BIND hereunder. Materials include, in the case of biological materials, all progeny and unmodified derivatives of those materials, and in the case of chemical materials, all analogs, formulations,
mixtures and compositions of those materials. 

  

	 	1.5	“Term” means the term of this Agreement as set forth in the Business Term Exhibit. 

 

	2.	Consulting Services. BIND retains Consultant and Consultant agrees to provide Consulting Services to BIND (the “Consulting Services”) as
it may from time to time reasonably request and as specified in the business terms exhibit attached to this Agreement (“Business Terms Exhibit”). Any changes to the Consulting Services (and any related compensation adjustments) must
be agreed upon in writing between Consultant and BIND prior to commencement of the changes. 

  

	3.	Consulting Relationship. Consultant agrees, as a condition of this Agreement, to the following terms: 

 

	 	3.1	Compliance. 

  

	 	a.	With Policies and Regulations. In performing the Consulting Services, Consultant will comply with all business conduct, regulatory, and health and safety
guidelines or regulations established by BIND or any governmental authority with respect to BIND’s business. 

  

	 	b.	Absence of Debarment. Consultant represents that Consultant has not been debarred, and to the best of Consultant’s knowledge, is not under consideration to
be debarred, by the U.S. Food and Drug Administration from working in or providing services to any pharmaceutical or biotechnology company under the Generic Drug Enforcement Act of 1992. 

	 	3.2	Absence of Restrictions. Consultant is under no contractual or other obligation or restriction which is inconsistent with Consultant’s execution of this
Agreement or the performance of the Consulting Services. During the Term, Consultant will not enter into any agreement, either written or oral, in conflict with Consultant’s obligations under this Agreement. Consultant will arrange to provide
the Consulting Services in such manner and at such times so that they will not conflict with Consultant’s responsibilities under any other agreement, arrangement or understanding or pursuant to any employment relationship Consultant has at any
time with any third party. 

  

	 	3.3	Confidential Information of Third Parties. The performance of the Consulting Services does not and will not breach any agreement which obligates Consultant to
keep in confidence any confidential or proprietary information of any third party or to refrain from competing, directly or indirectly, with the business of any third party. Consultant will not disclose to BIND any such confidential or proprietary
information. 

  

	4.	Compensation. As full consideration for Consulting Services rendered under this Agreement, BIND agrees to pay Consultant and reimburse expenses as set forth in
the Business Terms Exhibit. 

  

	5.	Developments. 

  

	 	5.1	Ownership. All Developments will be the exclusive property of BIND. All Developments that are “Works Made for Hire” as defined in the U.S. Copyright
Act and other copyrightable works will be deemed, upon creation, to be assigned to BIND. To the extent Developments have not been previously assigned to BIND, Consultant hereby assigns and, to the extent any such assignment cannot be made at
present, hereby agrees to assign to BIND, without further compensation, all right, title and interest in and to all Developments. During and after the Term, Consultant will cooperate fully in obtaining patent and other proprietary protection for the
Developments, all in the name of BIND and at BIND’s cost and expense, and, without limitation, will execute and deliver all requested applications, assignments and other documents, and take such other measures as BIND will reasonably request,
in order to perfect and enforce BIND’s rights in the Developments. Consultant appoints BIND its attorney to execute and deliver any such documents on Consultant’s behalf in the event Consultant fails to do so. 

 

	 	5.2	Work at Third Party Facilities. Unless covered by an appropriate agreement between any third party and BIND, Consultant wilt not engage in any activities or use
any third party facilities or intellectual property in performing the Consulting Services which could result in claims of ownership to any Developments being made by a third party. 

 

	6.	Confidentiality. During the Term and for a period of five (5) years thereafter, Consultant will not publish, disseminate or otherwise disclose, use for
Consultant’s own benefit or for the benefit of a third party, any Confidential Information. Consultant will exercise all reasonable precautions to physically protect the confidentiality of the Confidential Information. Consultant may disclose
the Confidential Information to a governmental authority or by order of a court of competent jurisdiction, provided that the disclosure is subject to all applicable governmental or judicial protection available for like material and reasonable
advance notice is given to BIND. The obligations of non-disclosure will not apply to information which (a) was known to Consultant at the time it was disclosed, other than by previous disclosure by BIND, as evidenced by Consultant’s
written records at the time of disclosure; (b) is at the time of disclosure or later becomes publicly known under circumstances involving no breach of this Agreement; or (c) is lawfully and in good faith made available to Consultant by a
third party who did not derive it, directly or indirectly, from BIND. 

  

	7.	Expiration/Termination. 

  

	 	7.1	Term. This Agreement will commence on the Effective Date and continue for the term specified on the Business Terms Exhibit (the “Term”), unless
sooner terminated pursuant to the express terms of this Section 7 or extended by mutual agreement of the parties. 

  

	 	7.2	Termination for Breach. If either party breaches in any material respect any of its material obligations under this Agreement, in addition to any other right or
remedy, the non-breaching party may terminate this Agreement in the event that the breach is not cured within thirty (30) days after receipt by that party of written notice of the breach. 

  
 Page 2 of 4

	 	7.3	Termination by BIND. BIND may terminate this Agreement (a) immediately at any time upon written notice to Consultant in the event of a breach of this
Agreement by Consultant which cannot be cured (i.e. breach of the confidentiality obligation) and/or (b) at any time without cause upon not less than fifteen (15) days’ prior written notice to Consultant. 

 

	 	7.4	Effect of Expiration/Termination. Upon expiration or termination, neither BIND nor Consultant will have any further obligations under this Agreement, except that
(a) the liabilities accrued through the date of expiration or termination, and (b) the terms of sections 1, 5, 6 and 8 will survive. Upon expiration or termination, and in any case upon BIND’s request, Consultant will return
immediately to BIND all Confidential Information and copies thereof. 

  

	8.	Miscellaneous. 

  

	 	8.1	Independent Contractor; Taxes. 

  

	 	a.	Independent Contractor. All Consulting Services will be rendered by Consultant as an independent contractor and this Agreement does not create an
employer-employee relationship between BIND and Consultant. Consultant will have no rights to receive any employee benefits, such as health and accident insurance, sick leave or vacation which are accorded to regular BIND employees. Consultant will
not in any way represent himself to be an employee, partner, joint venturer, agent or officer with or of BIND. 

  

	 	b.	Taxes. Consultant will pay all required taxes on Consultant’s income from BIND under this Agreement. Consultant will provide BIND with Consultant’s
taxpayer identification number or social security number, as applicable. 

  

	 	8.2	Use of Name. Consultant consents to the use by BIND of Consultant’s name and likeness in written materials and oral presentations to current or prospective
customers, partners, investors or others, provided that the materials or presentations accurately describe the nature of Consultant’s relationship with or contribution to BIND. 

 

	 	8.3	Notice. All notices must be written and sent to the address or facsimile number identified in this Agreement or a subsequent notice. All notices must be given
(a) by personal delivery, with receipt acknowledged; (b) by facsimile followed by hard copy delivered by the methods under (c) or (d); (c) by prepaid certified or registered mail, return receipt requested; or (d) by prepaid
recognized next business day delivery service. Notices will be effective upon receipt or as stated in the notice. Notices to BIND must be marked “Attention: Chief Executive Officer.” 

 

	 	8.4	Assignment. This Agreement is a personal services agreement, and the rights and obligations hereunder, may not be assigned or transferred by either party without
the prior written consent of the other party, except that BIND may assign this Agreement, in whole or in part, to an affiliated company or in connection with the merger, consolidation, sale or transfer of all or substantially all of the business to
which this Agreement relates. 

  

	 	8.5	Entire Agreement. This Agreement constitutes the entire agreement of the parties with regard to its subject matter, and supersedes all previous written or oral
representations, agreements and understandings between BIND and Consultant. 

  

	 	8.6	No Modification. This Agreement may be changed only by a writing signed by both parties. 

 

	 	8.7	Severability. Each provision in this Agreement is independent and severable from the others, and no provision will be rendered unenforceable as a result of any
other provision(s) being held to be invalid or unenforceable in whole or in part. If any provision of this Agreement is invalid, unenforceable or too broad, that provision will be appropriately limited and reformed to the maximum extent permitted by
applicable law. 

  

	 	8.8	Applicable Law. This Agreement will be governed by, and construed in accordance with, the laws of the Commonwealth of Massachusetts, U.S.A., without regard to
any choice of law principle that would dictate the application of the law of another jurisdiction. 

  
 Page 3 of 4

			
	BIND Biosciences, Inc.
		
	By	 	 /s/ Scott Minick

		 	duly authorized
		
	Print Name	 	 Scott Minick

		
	Title	 	 President & CEO

  

			
	CONSULTANT:
	
	/s/ Gregory Berk
	duly authorized
		
	Print Name	 	 Gregory Berk, MD

		
	Date	 	  

		
	Address	 	 332 S. McCadden Pl.

		
		 	 Los Angeles CA 90020

		
	Telephone	 	 925.719.3531

		
	Facsimile	 	  

		
	Tax ID or SS No.:	 	  

		 	(required for payment)

  
 Page 4 of 4

 BUSINESS TERMS EXHIBIT 

Consulting Agreement with Greg Berk 
  

	1.	Consulting Services: 

 Consultant shall
have the title of Senior Medical Advisor and serve in the capacity of full time Chief Medical Officer to help drive the preclinical and clinical development of BIND products, new opportunities for the use of BIND technology, regulatory approval for
BIND products, business development, commercialization activities, financing and other activities reasonably required to build a successful biotechnology company. Such services will be provided in a combination of locations including at least 4 days
per week at BIND’s offices or at other business meetings with BIND management. 
  

	2.	Compensation: 

  

	 	a.	Fees. Consultant will be paid $29,166.67 per month for consulting services for substantially all of consultant’s business time. 

 

	 	b.	Equity: The Company shall recommend to the Board of Directors to grant the Consultant a nonstatutory stock option (the Options) to purchase 292,342 shares (the
“Option Shares”) of common stock of the Company, $0.0001 par value per share (the “Common Stock”) at a purchase price equal to the fair market value (as determined by the Board of Directors) on the date of the grant. The Option
Shares shall become exercisable for 25% of such shares one year from the date of this agreement and then 2.083% per month for 36 months thereafter, so that the Option Shares shall be fully vested four years from the effective date of this
agreement. All vesting shall cease when the Consultant ceases to provide services as a consultant or employee. 

  

	 	c.	Expenses. BIND will reimburse Consultant for all reasonable and necessary expenses incurred by Consultant in rendering the Consulting Services, provided that
those expenses in excess of two hundred dollars ($200) per month have been approved in advance by BIND. Further, all expenses must be confirmed by appropriate written expense statements and other supporting documentation. 

 

	 	d.	Invoicing/Payments. On the last day of each calendar month, Consultant will invoice BIND for Consulting Services rendered and expenses incurred during the
preceding month. Invoices will contain detail as BIND may reasonably require and will be payable in U.S. Dollars. All undisputed payments will be made within forty five (45) days from BIND’s receipt of Consultant’s invoice.

  

	 	e.	Total contract. Total contract (inclusive of any expenses) is not to exceed $         per Terms of the Agreement, without
the prior written consent of BIND. 

  

	3.	Term: This Agreement will be for an initial term of six months beginning on the Effective Date (the “Term”).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]